Speaker(s): 

Glen R Finney MD, Staff Member, Geisinger - Consultant/Advisor: Lily, Novo-Nordisk, Premiere, Tonix

Learning Objectives: 

  • Utilize best practices for case finding of cognitively vulnerable adults, the options, limits, and best practices for evaluation of cognitive staging and pathologic causes.
  • Initiate evaluation and management of the cognitively vulnerable, including identifying and addressing reversible causes and contributors.
  • Identify the overlapping range of neurodegenerative causes of dementia. 
  • Explain the basics of identifying (including biomarkers) counseling, and acting upon benefits, costs, requirements, and risks of treatments of monoclonal antibodies against amyloid.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Stefanie Leader, DO, Stanley Martin, MD, Dan Dometita, DO, Malachi Courtney, MD, Eric Hossler, DO, Stacey Coolbaugh, RDN, and Donald Weider, PA-C have no identified disclosures. 
 
CE Committee Member/Content Reviewers have nothing to disclose. 
Tammy McCormick, RDN, and Timothy Murphy, MD
 
Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None

Session date: 
04/03/2026 - 12:00pm to 1:00pm EDT
Location: 
Virtual via Microsoft Teams
Danville, PA 17822
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AAPA Category I CME
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 CDR
  • 1.00 Participation Credit
Please login or register to take this course.